Federal Court Reconsiders Civil Ruling in False Claims Act Case

In a significant legal development, a U.S. District Court has denied medical device giant Medtronic’s request for reconsideration of a previously rejected motion for summary judgment in a False Claims Act (FCA) case, determining that evidence presented by the plaintiff remains sufficient even under a stricter causation standard.

The case involves allegations that Medtronic provided improper remuneration to healthcare providers related to its iPro2/iPro continuous glucose monitoring device, potentially violating the Anti-Kickback Statute (AKS).

Judge Indira Talwani ruled that while the court would reconsider its prior analysis in light of a recent First Circuit decision in United States v. Regeneron Pharmaceuticals, Inc., the outcome would remain unchanged. The Regeneron case established that the phrase “resulting from” in the 2010 amendment to the AKS requires but-for causation—a more demanding standard than previously applied.

“Although the court previously rejected the application of a but-for causation standard, the court now finds Witkin proffered evidence sufficient to survive summary judgment under such a standard,” Judge Talwani wrote in her 12-page opinion.

The case was initiated by whistleblower Adam Witkin, who presented evidence that Medtronic field personnel were instructed to work directly with medical offices to identify and schedule patients, bring Medtronic-owned equipment to offices, place devices on patients, and provide training—activities that could constitute illegal remuneration under the AKS.

Particularly compelling was evidence showing that these “demonstration clinics” were explicitly designed to drive sales of Medtronic products. In one example highlighted by the court, Medtronic implemented “weekly iPro clinics” at a previously “stagnant” physician’s office, resulting in an 850% growth in Medtronic pump prescriptions at that location.

The court found this evidence more substantial than the mere “temporal proximity” questioned in the Regeneron case. Judge Talwani determined that a reasonable jury could infer that Medtronic’s extensive activities influenced healthcare providers’ decision-making and led to the submission of false claims to government healthcare programs.

The ruling represents a significant development in healthcare fraud enforcement, particularly regarding the interpretation of the 2010 AKS amendment that explicitly linked AKS violations to FCA liability. The healthcare industry has been closely watching how courts interpret this connection, as it affects compliance programs and business practices of medical device manufacturers, pharmaceutical companies, and other healthcare entities.

For Medtronic, one of the world’s largest medical technology companies, the case could have far-reaching implications for its sales and marketing practices. The company, which reported over $30 billion in annual revenue last year, has a substantial stake in the diabetes care market where continuous glucose monitoring devices like the iPro represent a growing segment.

The medical device industry as a whole has faced increasing scrutiny over marketing practices and relationships with healthcare providers. Companies often provide training, education, and support services related to their products, creating potential gray areas under anti-kickback regulations.

Judge Talwani granted Medtronic’s motion for reconsideration only regarding the per se theory of FCA liability, while denying it for the false certification theory. However, even with the reconsideration, the court ultimately denied Medtronic’s underlying motion for summary judgment, allowing the case to proceed toward trial.

The ruling in United States ex rel. Witkin v. Medtronic, Inc., et al. underscores the complexity of healthcare fraud cases and the evolving standards courts apply when interpreting anti-kickback provisions. As healthcare costs continue to rise, government enforcement agencies and whistleblowers have increasingly targeted alleged kickback arrangements that may drive unnecessary utilization and costs to federal healthcare programs.